Treatment of systemic sclerosis.

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Systemic sclerosis (scleroderma) is a complex autoimmune disease characterized by fibrosis and vascular abnormalities.
• Accurate patient classification into diffuse cutaneous and limited cutaneous subsets is crucial for predicting disease progression and complications.

Purpose of the Study:

• To outline key management strategies for systemic sclerosis.
• To identify high-risk patient groups and potential therapeutic targets.
• To highlight recent advancements in treating scleroderma complications, particularly renal disease.

Main Methods:

• Review of current understanding of systemic sclerosis pathophysiology.
• Identification of patient subsets based on disease presentation and progression.
• Discussion of therapeutic targets including vascular endothelium, mononuclear cells, and fibroblasts.
• Evaluation of emerging treatments and established interventions for organ-specific complications.

Main Results:

• Patients with early diffuse systemic sclerosis and rapid skin thickening face the highest risk of internal organ involvement (gastrointestinal, pulmonary, cardiac, renal).
• Angiotensin-converting enzyme inhibitors and advanced renal replacement therapies have shown success in reversing scleroderma-related kidney disease.
• Ongoing therapeutic trials are investigating new agents targeting specific disease pathways.

Conclusions:

• Effective management of systemic sclerosis relies on precise patient classification and proactive complication anticipation.
• Disease-modifying treatments should be considered for high-risk patients with early diffuse disease.
• Systemic sclerosis is a manageable condition with significant advancements in treatment, offering hope for improved patient outcomes.